Urokinase plasminogen activator upregulates paraoxonase 2 expression in macrophages via an NADPH oxidase-dependent mechanism

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 28, Issue 7, 2008, Pages 1361-1367

  Fuhrman, Bianca ^a   Khateeb, Jasmin ^a   Shiner, Maayan ^a   Nitzan, Orna ^b   Karry, Rachel ^a   Volkova, Nina ^a   Aviram, Michael ^a  

^a RAMBAM MEDICAL CENTER   (Israel)

^b HAEMEK MEDICAL CENTER   (Israel)

Author keywords

Antioxidants; Macrophages; NADPH oxidase; Paraoxonase 2 (PON2); Urokinase

Indexed keywords

ANTIOXIDANT; ARYLDIALKYLPHOSPHATASE 2; LIPID PEROXIDE; LOW DENSITY LIPOPROTEIN; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SUPEROXIDE; UROKINASE; UROKINASE RECEPTOR; ACETOPHENONE DERIVATIVE; APOCYNIN; ARYLDIALKYLPHOSPHATASE; CELL SURFACE RECEPTOR; MESSENGER RNA; NEUTROPHIL CYTOSOLIC FACTOR 1; OXIDIZED LOW DENSITY LIPOPROTEIN; PLANT EXTRACT; PON2 PROTEIN, HUMAN; UROKINASE TYPE PLASMINOGEN ACTIVATOR RECEPTORS; UROKINASE-TYPE PLASMINOGEN ACTIVATOR RECEPTORS;

ANIMAL CELL; ARTICLE; CELL LEVEL; CELL PROTECTION; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME MECHANISM; GENE FUNCTION; HUMAN; HUMAN CELL; LIPID PEROXIDATION; MACROPHAGE; MOUSE; NONHUMAN; OXIDATION; OXIDATIVE STRESS; PERITONEUM MACROPHAGE; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; UPREGULATION; ANIMAL; ATHEROSCLEROSIS; BAGG ALBINO MOUSE; BIOSYNTHESIS; C57BL MOUSE; DRUG EFFECT; ENZYME INDUCTION; ENZYMOLOGY; GENETICS; METABOLISM; MOUSE MUTANT; POMEGRANATE; TUMOR CELL LINE;

ACETOPHENONES; ANIMALS; ANTIOXIDANTS; ARYLDIALKYLPHOSPHATASE; ATHEROSCLEROSIS; CELL LINE, TUMOR; ENZYME ACTIVATION; ENZYME INDUCTION; HUMANS; LIPID PEROXIDATION; LIPOPROTEINS, LDL; MACROPHAGES; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, KNOCKOUT; NADPH OXIDASE; OXIDATIVE STRESS; PLANT EXTRACTS; PUNICACEAE; REACTIVE OXYGEN SPECIES; RECEPTORS, CELL SURFACE; RNA, MESSENGER; URINARY PLASMINOGEN ACTIVATOR;

EID: 46249131854     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/ATVBAHA.108.166041     Document Type: Article

References (38)

1. Stocker K, Reaney JF Jr. New insights on oxidative stress in the artery wall. J Thromb Haemost. 2005;3:1825-1834.
2. Fuhrman B, Oiknine J, Aviram M. Iron induces lipid, peroxidation in cultured macrophages, increases their ability to oxidatively modify LDL, and affects their secretory properties. Atherosclerosis. 1994;111:65-78.
3. Fuhrman B, Judith O, Reidar S, Ben-Yaish L, Raplan. M, Aviram M. Increased uptake of LDL by oxidized macrophages is the result of an. initial enhanced LDL receptor activity and of a further progressive oxidation, of LDL. Free Radie Biol Med. 1997;23:34-46.
4. Fuhrman B, Volkova N, Aviram. M. Oxidative stress increases the expression of the CD36 scavenger receptor and the cellular uptake of oxidized low-density lipoprotein in macrophages from atherosclerotic mice: protective role of antioxidants and of paraoxonase. Atherosclerosis. 2002;161:307-316.
5. Waltz DA, Fujita RM, Yang X, Natkin L, Zhuo S, Gerard CJ, Rosenberg S, Chapman. HA. Nonproteolytic role for the urokinase receptor in cellular migration in vivo. Am J Respir Cell Mol Biol. 2000;22:316-322.
6. Gyongyosi M, Glogar D, Weidinger F, Domanovits H, Laggner A, Wojta J, Zom. G, Iordanova N, Huber R. Association between plasmin activation system and intravascular ultrasound signs of plaque instability in patients with, unstable angina and non-st-segment elevation myocardial infarction. Am. Heart J. 2004;147:158-164.
7. Rienast J, Padro T, Steins M, Li CX, Schmid RW, Hammel D, Scheid HH, van de Loo JC. Relation of urokinase-type plasminogen activator expression, to presence and severity of atherosclerotic lesions in human coronary arteries. Thromb Haemost. 1998;79:579-586.
8. Padro T, Emeis JJ, Steins M, Schmid RW, Rienast J. Quantification of plasminogen activators and their inhibitors in the aortic vessel wall in relation, to the presence and severity of atherosclerotic disease. Arterioscler Thromb Vase Biol. 1995;15:893-902.
9. Lupu F, Heim. DA, Bachmann F, Hurni M, Rakkar VV, Rruithof ER. Plasminogen, activator expression in human atherosclerotic lesions. Arterioscler Thromb Vase Biol. 1995;15:1444-1455.
10. Cozen AE, Moriwaki H, Rremen M, De Young MB, Dichek HL, Slezicki KI, Young SG, Veniant M, Dichek DA, Macrophage-targeted. overexpression of urokinase causes accelerated atherosclerosis, coronary artery occlusions, and premature death. Circulation. 2004;109:2129-2135.
11. Bianca Fuhrman, Orna Nitzan, Rachel Rarry, Nina Volkova, Inna DumleK, Michael Aviram. Urokinase plasminogen activator (uPA) stimulates cholesterol biosynthesis in macrophages through activation of SREBP-1 in a PI3-kinase and MEK-dependent manner. Atherosclerosis. 2007;195:e108-e116.
12. La Du BN. Structural and functional diversity of paraoxonases. Nat Med. 1996;2:1186-1187.
13. Ng CJ, Wadleigh DJ, Gangopadhyay A, Hama S, Grijalva VK, Navab M, Fogelman AM, Reddy ST. Paraoxonase-2 is a ubiquitously expressed protein with antioxidant properties and is capable of preventing cellmediated oxidative modification, of low density lipoprotein. J Biol Chem. 2001;276:44444-44449.
14. Ng CJ, Hama SY, Bourquard N, Navab M, Reddy ST. Adenovirus mediated expression of human, paraoxonase 2 protects against the development of atherosclerosis in apolipoprotein E-deficient mice. Mol Genet Metab. 2006;89:368-373.
15. Ng CJ, Bourquard. N, Grijalva V, Hama S, Shih DM, Navab M, Fogelman AM, Lusis AJ, Young S, Reddy ST. Paraoxonase-2 deficiency aggravates atherosclerosis in. mice despite lower apolipoprotein-B-containing lipoproteins: anti-atherogenic role for paraoxonase-2. J Biol Chem, 2006; 281:29491-29500.
16. Horke S, Witte I, Wilgenbus P, Rruger M, Strand D, Forstermann U. Paraoxonase-2 reduces oxidative stress in. vascular cells and decreases endoplasmic reticulum, stress-induced caspase activation, Circulation. 2007;115:2055-2064.
17. Rosenblat M, Draganov D, Watson CE, Bisgaier CL, La Du BN, Aviram. M. Mouse macrophage paraoxonase 2 activity is increased whereas cellular paraoxonase 3 activity is decreased under oxidative stress. Arterioscler Thromb Vase Biol. 2003;23:468-474.
18. Shiner M, Fuhrman B, Aviram M. Paraoxonase 2 (PON2) expression is upregulated via a reduced-nicotinamide-adenine-dinucleotide-phosphate (NADPH)-oxidase-dependent mechanism during monocytes differentiation, into macrophages. Free Radie Biol Med. 2004;37:2052-2063.
19. Shiner M, Fuhrman B, Aviram M. A biphasic U-shape effect of cellular oxidative stress on the macrophage anti-oxidant paraoxonase 2 (PON2) enzymatic activity. Biochem Biophys Res Commun. 2006;349: 1094-1099.
20. Shiner M, Fuhrman B, Aviram M. Macrophage paraoxonase 2 (PON2) expression, is up-regulated by pomegranate juice phenolic anti-oxidants via PPARgamma and AP-I pathway activation. Atherosclerosis. 2007; 195:313-321.
21. Fuhrman. B, Shiner M, Volkova N, Aviram M. Cell-induced copper ion-mediated low density lipoprotein oxidation increases during in vivo monocyte-«)-macrophage differentiation, Free Radie Biol Med. 2004;37: 259-271.
22. Aviram M, Vaya J. Markers for low-density lipoprotein oxidation. Methods Enzymol. 2001;335:244-256.
23. Sohn HY, Relier M, Gloe T, Morawietz H, Rueckschloss U, Pohl U. The small G-protein Rae mediates depolarization-induced superoxide formation in human endothelial cells. J Biol Chem. 2000;275:18745-18750.
24. Draganov D, Stetson PL, Watson C, Billecke S, La Du BN. Rabbit serum paraoxonase 3 (PON3) is a high-density lipoprotein-associated lactonase and protects low-density lipoprotein against oxidation. J Biol Chem, 2000;275:33435-33442.
25. Solberg H, Lober D, Eriksen J, Ploug M, Ronne E, Behrendt N, Dano K, Hoyer-Hansen. G. Identification and characterization, of the murine cell surface receptor for the urokinase-type plasminogen, activator. Eur J Biochem. 1992;205:451-458.
26. Aviram M, Dornfeld L, Rosenblat M, Volkova N, Raplan. M, Coleman. K, Hayek T, Presser D, Fuhrman B. Pomegranate juice consumption reduces oxidative stress, atherogenic modifications to LDL, and platelet aggregation: studies in humans and in atherosclerotic apolipoprotein E-deficient mice. Am. J Clin Nutr. 2000;71:1062-1076.
27. Halliwell B. Oxidative stress in cell culture: an under-appreciated problem? FEBS Lett. 2003;540:3-6.
28. Jackson SH, Gallin JI, Holland SM. The p47phox mouse knock-out model of chronic granulomatous disease. J Exp Med. 1995;182:751-758.
29. Ranse SM, Benzakour O, Ranthou C, Kost C, Lijnen HK, Preissner KT. Induction of vascular SMC proliferation by urokinase indicates a novel mechanism of action, in vasoproliferative disorders. Arterioscler Thromb Vase Biol. 1997;17:2848-2854.
30. Plekhanova O, Parfyonova Y, Bibilashvily K, Domogatskii S, Stepanova V, Gulba DC, Agrotis A, Bobik A, Tkachuk V. Urokinase plasminogen activator augments cell proliferation and neointima formation in injured arteries via proteolytic mechanisms. Atherosclerosis. 2001;159:297-306.
31. Aviram M, Rosenblat M, Etzioni A, Levy R. Activation, of NADPH oxidase required for macrophage-mediated oxidation of low-density lipoprotein. Metabolism. 1996;45:1069-1079.
32. Berliner JA, Navab M, Fogelman AM, Frank JS, Demer LL, Edwards PA, Watson AD, Lusis AJ. Atherosclerosis: basic mechanisms. Oxidation, inflammation, and genetics. Circulation, 1995;91:2488-2496.
33. Cao D, Mizukami IF, Garni-Wagner BA, Kindzelskii AL, Todd RF III, Boxer LA, Petty HR. Human urokinase-type plasminogen activator primes neutrophils for superoxide anion release. Possible roles of complement receptor type 3 and calcium. J Immunol. 1995;154:1817-1829.
34. Menshikov M, Plekhanova O, Cai H, Chalupsky K, Parfyonova Y, Bashtrikov P, Tkachuk V, Berk. BC. Urokinase plasminogen activator stimulates vascular smooth muscle cell proliferation via redox-dependent pathways. Arterioscler Thromb Vase Biol. 2006;26:801-807.
35. Cave AC, Brewer AC, Narayanapanicker A, Ray K, Grieve DJ, Walker S, Shah AM. NADPH oxidases in cardiovascular health and disease. Antioxid Redox Signal. 2006;8:691-728.
36. Nie L, Wu G, Zhang W. Correlation of mRNA expression and protein, abundance affected by multiple sequence features related to translational efficiency in Desulfovibrio vulgaris: a quantitative analysis. Genetics. 2006;174:2229-2243.
37. Stocker K, Keaney JF Jr. Role of oxidative modifications in. atherosclerosis. Physiol. Rev. 2004;84:1381-1478.
38. Stoppelli MP, Corti A, Soffientini A, Cassani G, Blasi F, Assoian RR. Differentiation-enhanced binding of the amino-terminal fragment of human urokinase plasminogen activator to a specific receptor on U937 monocytes. Proc Natl Acad Sci USA. 1985;82(15):4939-4943.